Overview

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Status:
WITHDRAWN

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
copanlisib